Evogen, Inc.
Lower Gwynedd, US
Evogen develops proteomics and genomics diagnostic technologies for neurology precision medicine, including a biomarker-based blood test (EvoScore) for epilepsy and seizure diagnosis. The company also offers HyBeacons PCR reagent technology for pathogen detection and the SpinCon air sampler for collecting airborne biothreats, serving healthcare providers and biodefense applications.
BiotechHealthtechMedical Devices
Founders & leadership
TM
Todd M. WallachCEO / President
JM
John M. GledhillDirector of R&D and Lab Operations
RD
Richard D. St.ClairVP, Commercial Operations
NL
Nathan LedeboerNamed on SEC filing
HK
Hans KastensmithNamed on SEC filing
RS
Richard St. ClairNamed on SEC filing
JL
Jonathan LeitersdorfNamed on SEC filing
RD
Robert DondesNamed on SEC filing
SR
Sean ReinekeNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$852.4K disclosed across 1 round · 2014
▶$852.4KraisedFeb 2014 · 8 investors · BiotechnologyRule 506(b)
▶$852.4KraisedFeb 2014 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Nathan LedeboerDirector
- Hans KastensmithExecutive Officer, Director, Promoter
- Richard St. ClairExecutive Officer
- Jonathan LeitersdorfDirector
- Robert DondesExecutive Officer
- Sean ReinekeDirector
- Offering amount
- $1.6M
- Amount sold
- $852.4K
- First sale
- Jan 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 5 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $617.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $224.5K |
| U.S. ArmyArmy | Phase II | 2012 | $720K |
| U.S. ArmyArmy | Phase I | 2011 | $69.5K |
| Department of Homeland Security | Phase I | 2006 | $98.5K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Evogen, Inc. do?
- Evogen develops proteomics and genomics diagnostic technologies for neurology precision medicine, including a biomarker-based blood test (EvoScore) for epilepsy and seizure diagnosis. The company also offers HyBeacons PCR reagent technology for pathogen detection and the SpinCon air sampler for collecting airborne biothreats, serving healthcare providers and biodefense applications.
- How much funding has Evogen, Inc. raised?
- Evogen, Inc. has disclosed $852.4K raised across 1 round.
- Where is Evogen, Inc. headquartered?
- Evogen, Inc. is headquartered in Lower Gwynedd, US.